Comparative Pharmacology
Head-to-head clinical analysis: ENLON versus MESTINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENLON versus MESTINON.
ENLON vs MESTINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, inhibiting neuromuscular transmission.
Inhibits acetylcholinesterase, preventing breakdown of acetylcholine and increasing its concentration at cholinergic synapses, thereby enhancing neuromuscular transmission.
Intravenous: 0.1 mg/kg followed by 1-2 mg/min infusion for reversal of neuromuscular blockade; adjust based on twitch response.
Myasthenia gravis: 60-150 mg orally every 3-4 hours, up to 1.2 g/day. Extended-release: 180-540 mg orally once or twice daily.
None Documented
None Documented
Terminal elimination half-life of 1.5-2.5 hours; prolonged in renal impairment and elderly patients
The terminal elimination half-life is approximately 1.5 to 2 hours in adults. In patients with renal impairment, half-life may be prolonged (up to 6-10 hours in severe impairment), necessitating dose adjustment.
Primarily renal excretion of unchanged drug (85-95%), with minor fecal elimination (<5%)
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of elimination, with a small fraction (10-20%) eliminated in feces via biliary secretion.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor